Newsroom

Cell therapies show remarkable potential in treating challenging lymphomas, as demonstrated by real-world data. But companies may run out of funds before reaching milestones due to factors like inefficient manufacturing, facility costs, and difficulties scaling processes. Alaina Schlinker, Ph.D., Senior Manager, Field Applications Support, ScaleReady, discusses how ScaleReady's platforms aim to help developers reach clinical milestones quickly and cost-effectively.

In an exclusive interview with RegMedNet, Jenny Stjernberg discusses the crucial role of scalability in advancing groundbreaking therapies. Stjernberg emphasizes the importance of preserving flexibility while scaling up cell therapy manufacturing approaches.

Watch the roundtable discussion from Medicine Maker featuring experts from ScaleReady, Terumo Blood and Cell Technologies, Orgenesis, and BioBridge Global.

In this edition of Pharma's Almanac, industry experts, including Josh Ludwig, Global Director of ScaleReady, discuss increased innovation and adoption of artificial intelligence (AI) and machine learning in biopharma.

In this expert roundtable, David McCall, Senior Editor, BioInsights, speaks to Anastasiya Smith, Senior Director of R&D, CellReady; Josh Ludwig, Global Director, Commercial Operations, ScaleReady; and David Hermanson, Senior Manager of R&D Applications, Cell and Gene Therapy, Bio-Techne.

Terumo’s Stuart Gibb, Ph.D., at Terumo Blood and Cell Technologies, is joined by Nisha C. Durand, PhD, at Mayo Clinic and Matthew M. Hewitt, B.A. Ph.D., Charles River.